Investor Relations

Investor Relations

LifeShield Technologies is seeking mission-aligned seed investors to fund independent laboratory testing, prototype development, and intellectual-property protection for our antimicrobial gauze platform.

The Opportunity

21,100 Lives Lost Every Day. We Are Building a Better Gauze.

The Problem: Bacterial infections kill 7.7 million people every year — more than 21,100 lives lost every single day. That is 1 in 8 deaths globally. Wound infections are a significant and preventable contributor to this crisis, and the standard wound care gauze used by clinicians and first responders has not fundamentally changed.

The Technology Platform: LifeShield is developing a proprietary antimicrobial formulation designed to be integrated directly into the fibers of gauze pads and rolled gauze — not applied as a surface coating. Our founder, U.S. Navy Veteran Dovid Ben Yehuda, brings 25 years of textile and garment manufacturing experience to this development effort, combined with a personal history of surviving sepsis from non-healing wounds now being treated by the VA.

The Initial Application: Gauze pads and rolled gauze are our first and primary product focus. This is where the need is most acute, the manufacturing pathway is most direct, and the founder's expertise is most relevant. Apparel, bedding, and other textiles are potential future applications — but gauze comes first.

The Next Milestone: Independent laboratory validation. We have not yet completed third-party testing, and we will not make performance claims until we have credible, reproducible results from accredited laboratories. This seed round funds that milestone directly.

The Future Market: A validated antimicrobial gauze platform creates a foundation for expansion into the broader antimicrobial textile market — projected to exceed $1 billion globally — including apparel, bedding, and healthcare textiles. Investors who come in at seed stage participate in the full upside of that platform.

Why LifeShield

What Sets Us Apart

Veteran-Led. Mission-Proven.

Founded by a U.S. Navy Veteran and service-connected disabled veteran with 25 years in textiles. Dovid Ben Yehuda did not find this problem in a market report — he survived it. Investors can trust that we will see this through.

Proprietary Technology Platform

Our antimicrobial formulation is proprietary, with intellectual-property protections being pursued as development progresses — creating a defensible competitive position as we move toward independent validation and commercialization.

Focused Initial Market

We are not trying to do everything at once. Gauze pads and rolled gauze are a focused, high-need starting point — used by clinicians, first responders, and patients worldwide. A validated gauze platform is the foundation for everything that follows.

Science-First Credibility

We do not make claims we cannot prove. Independent validation is our next milestone — not a future aspiration. That commitment to honest science is the foundation of trust with investors, partners, regulators, and consumers.

Current Stage

Where We Are Today

LifeShield Technologies is an early-stage company in active technology development. We are developing our proprietary antimicrobial formulation for gauze pads and rolled gauze, pursuing intellectual-property protections, and preparing for independent laboratory testing. We are currently seeking seed investment to fund prototype manufacturing, third-party validation, and the essential work required to advance the project responsibly toward commercialization.

Seed Funding

Our $50,000 Funding Goal

LifeShield Technologies is seeking $50,000 in seed funding to support independent laboratory testing, prototype development, intellectual-property protection, and the essential work required to advance the project responsibly.

Priority: $50,000 Funding Needed

Fund the next critical milestone: independent validation.

This $50,000 raise supports a focused, milestone-based program: representative gauze samples, independent third-party testing, intellectual property protection, and responsible commercialization preparation.

Funding Goal

$50,000

100% Milestone-Directed

Use of FundsAllocation
Prototype manufacturing & gauze samples$15,000
Independent laboratory testing$10,000
Product development & engineering$7,000
Intellectual property & patent protection$6,000
Regulatory preparation & documentation$5,000
Business development & demonstration materials$4,000
Contingency reserve$3,000
Total Funding Goal$50,000

Independent testing precedes any commercial performance claims.

Veteran-Founded Company

Founded by a U.S. Navy Veteran

LifeShield Technologies is founded and led by Dovid Ben Yehuda, a U.S. Navy Veteran and service-connected disabled veteran. As a veteran-owned small business, LifeShield is pursuing SDVOSB certification — a designation that would open access to federal contracting set-asides, VA procurement channels, and non-dilutive SBIR/STTR grant funding designed to support veteran-led innovation.

Veteran Founded

Founded and led by a U.S. Navy Veteran with 25 years of textile manufacturing experience and a personal history of surviving sepsis from service-connected wounds.

SBIR/STTR Eligible

As a small business in biotech R&D, LifeShield is eligible for SBIR and STTR grants — non-dilutive federal funding specifically for early-stage technology development.

VA Partnership Pathway

SDVOSB certification (being pursued) would create a direct pathway to VA procurement — one of the largest healthcare buyers in the world, with a mission aligned with LifeShield's.

Why Now

The Window Is Open

7.7Mdeaths per year

Bacterial infections are the second leading infectious cause of death globally — and better wound care tools at the point of care remain a largely unmet need.

$1B+antimicrobial textile market

The global antimicrobial textile market is projected to exceed $1 billion — driven by healthcare, military, and consumer demand for passive protection integrated into everyday products.

Seedstage — early entry

Investing at seed stage means early equity, maximum upside, and the opportunity to shape the company's direction before the technology is validated and the market opens.

QR code linking to the LifeShield investor inquiry page
Investor Access

Scan to Reach Our Investor Page

Share this QR code at events, in print materials, or with your network. It links directly to this investor page so qualified contacts can learn about LifeShield and submit an inquiry instantly — no URL to type.

Download QR Codelifeshieldprevention.com/investors
Investor Inquiries

Get in Touch

We welcome inquiries from qualified investors. Please complete the form below and a member of our team will be in touch.

LifeShield

Developing proprietary antimicrobial technology for gauze pads, rolled gauze, apparel, bed sheets, and pillowcases — protecting people from harmful bacteria through the products they already rely on.

© 2026 LifeShield Technologies. All rights reserved.

All technology, formulations, and processes described herein are proprietary and confidential. Unauthorized reproduction or disclosure is strictly prohibited.